Johnson & Johnson Acquires Intra-Cellular Therapies

AbbVie Acquires Capstan Therapeutics

August 19, 2025

Biotechnology

AbbVie has completed its acquisition of Capstan Therapeutics, adding Capstan's lead asset CPTX2309 — an in vivo targeted lipid nanoparticle (tLNP) anti‑CD19 CAR‑T candidate in Phase 1 for B cell‑mediated autoimmune diseases — and a proprietary tLNP RNA delivery platform. The deal strengthens AbbVie's immunology pipeline and expands its in vivo cell‑programming capabilities for RNA payload delivery.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion

December 29, 2025

Biotechnology

Johnson & Johnson completed the acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash, adding Halda's RIPTAC platform and clinical-stage prostate cancer candidate HLD-0915 to its oncology portfolio. The deal brings several earlier-stage RIPTAC-based programs for other solid tumors and positions J&J to advance oral targeted therapies that may overcome treatment resistance.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Novartis Acquires Cadent Therapeutics

December 17, 2020

Biotechnology

Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts–based clinical‑stage neuroscience company, adding two clinical‑stage programs for schizophrenia and movement disorders plus the buyout of MIJ821 milestones/royalties. The deal (reported up to $770 million including milestones) strengthens Novartis' neuropsychiatry portfolio and is expected to close in Q1 2021 subject to customary conditions.